<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923152</url>
  </required_header>
  <id_info>
    <org_study_id>IR.SUMS.MED.REC.1398.620</org_study_id>
    <nct_id>NCT04923152</nct_id>
  </id_info>
  <brief_title>Effective Dose of Statin Post PCI</brief_title>
  <official_title>Effects of High- or Moderate-Dose Statin on 1-Year Major Adverse Cardiovascular Events (MACE) Post Percutaneous Coronary Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study post coronary stenting patients, were enrolled to receive moderate dose versus&#xD;
      high dose statin for 1 year, and the result of major adverse cardiovascular events were&#xD;
      recorded&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized double-blind clinical trial, the study population was all patients with a&#xD;
      recent history of PCI who referred to the professor kojuri cardiovascular clinic for the&#xD;
      first post-procedure visit. In the first visit, patients were randomly divided into two&#xD;
      groups Both groups were treated with Rosuvastatin 40 mg as high potency statin for one month&#xD;
      after PCI. In the first group, after one month, the statin level changed to Rosuvastatin 5 mg&#xD;
      daily (moderate intensity). In the second group, 40 mg of Rosuvastatin was continued for one&#xD;
      year. Then, the participants were evaluated in terms of MACEs, including any hospitalization&#xD;
      due to acute coronary syndrome, as well as history of stroke and myocardial Infarction,&#xD;
      subsequent unplanned revascularization and cardiac death. The HS-CRP also checked between two&#xD;
      groups&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Group A, group B</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>major adverse cardiovascular events (MACE)</measure>
    <time_frame>1 year</time_frame>
    <description>major adverse cardiovascular events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum level of HS-CRP</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">582</enrollment>
  <condition>Statin Dose</condition>
  <arm_group>
    <arm_group_label>moderate dose statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 1 month post PCI, allocated to 5 mg rosuvastatin per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients 1 month post PCI, allocated to 40 mg rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moderate statin dose</intervention_name>
    <description>5 mg rosuvastatin per day</description>
    <arm_group_label>moderate dose statin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose statin</intervention_name>
    <description>40 mg rosuvastatin per day</description>
    <arm_group_label>high dose statin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients who have undergone PCI due to chronic stable angina&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute coronary syndrome&#xD;
&#xD;
          -  Primary LDL&gt;190 mg/DL&#xD;
&#xD;
          -  Patients who developed statin-induced myopathy or rhabdomyolysis&#xD;
&#xD;
          -  Persistent increase in hepatic enzyme levels or hepatic failure&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Statin hypersensitivity&#xD;
&#xD;
          -  Patients with history of multiple atherosclerotic events&#xD;
&#xD;
          -  Patients who received high intensity statin before the study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>52 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Professor kojuri cardiology clinic</name>
      <address>
        <city>Shiraz</city>
        <state>Outside Of The US</state>
        <zip>55318</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Javad Kojuri</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>Stable Angina</keyword>
  <keyword>statin therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Dat available on demand of reviewer</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

